OCUGEN, INC. Available-for-sale Securities, Gross Unrealized Loss
OCUGEN, INC. (OCGN) reported Available-for-sale Securities, Gross Unrealized Loss of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2017-11-09
- OCUGEN, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2017-09-30 was -$2.00K.
- OCUGEN, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2017-06-30 was -$4.00K.
- OCUGEN, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2017-03-31 was $6.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month |
|---|---|---|---|
| 2017-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$6.00K derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.00K 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $6.00K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |